ASCO 2025: Focus on Treatment Sequencing in mBC
Advertisement
Dr. Gradishar on Managing Toxicities and Tailoring Treatment in HER2+ mBC
William J. Gradishar, MDHER2 Breast Cancer | June 5, 2025
Dr. Gradishar discusses how tolerability, toxicity, and NCCN guidelines shape HER2+ breast cancer treatment decisions.
View More
Sequencing HER2-Targeted Therapies: What Comes After THP?
William J. Gradishar, MDHER2 Breast Cancer | June 5, 2025
Dr. William Gradishar discusses treatment sequencing strategies for HER2+ metastatic breast cancer at ASCO 2025.
View More
Advertisement
Advertisement
Advertisement
Latest News

Piperacillin May Be a Promising Targeted Therapy for Lyme Disease

July 2, 2025

Bringing Clinical Trials to Patients: A Vision for Accessible Cancer Research

July 2, 2025

New AI Tool Boosts Accuracy in HER2-Low and HER2-Ultralow Breast Cancer Scoring

July 1, 2025

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Editorial Policy

    Advertising

    Connect

    Contact Us

    eNewsletters

    Contribute

    Career Center

    Our Network

    MashupMD

    Blood Cancers Today

    Cancer Nursing Today

    GU Oncology Now

    Urban Health Today

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |